Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Simple Summary Since the first antibody–drug conjugate (ADC) was approved in 2000, the
landscape of these targeted drugs has evolved over the years, profoundly changing the …

The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …

Immunoengineering is a rapidly evolving field that has been driving innovations in
manipulating immune system for new treatment tools and methods. The need for materials …

Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system.
Although there are various treatment modalities, including surgery, chemotherapy, and …

In recent years, remarkable breakthroughs have been reported on antibody‐drug
conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade …

Biocatalysis can be defined as the use of isolated enzymes or enzymes inside cells to
convert substrates into products. The term “biocatalysis” is often used in modern organic …

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant
promise for patients with cancer, particularly where existing treatments are limited …

Simple Summary The goal of this work was to improve the tumor selectivity of chemotherapy
to reduce side effects and improve efficacy. We designed a drug called VIP236 that delivers …

Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against
tumor cells. China approved T‐Dxd in May 2023, and their introduction has changed the …